Phase III trial of CHOP-21 versus CHOP-14 for aggressive non-Hodgkin's lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG 9809.

@article{Ohmachi2011PhaseIT,
  title={Phase III trial of CHOP-21 versus CHOP-14 for aggressive non-Hodgkin's lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG 9809.},
  author={Ken Ohmachi and Kensei Tobinai and Yusuke Kobayashi and Kuniaki Itoh and Masanobu Nakata and Tatsuhiro Shibata and Yasuo Morishima and M Kitamura Ogura and Tetsuro Suzuki and Ryzo Ueda and Keiko Aikawa and Shigeo Nakamura and Haruhiko Kawasaki Fukuda and Masanori Shimoyama and Tomomitsu Hotta},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2011},
  volume={22 6},
  pages={
          1382-91
        }
}
BACKGROUND CHOP-21 has remained the standard chemotherapy for aggressive non-Hodgkin's lymphoma (NHL), and dose intensification is a potential strategy for improving therapeutic results. We conducted a phase III trial to determine whether dose-dense strategy involving interval shortening of CHOP (CHOP-14) is superior to CHOP-21. PATIENTS AND METHODS A total of 323 previously untreated patients (aged 15-69 years) with stages II-IV aggressive NHL were randomized. The primary end point was… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 11 CITATIONS

Lymphoma study group of JCOG.

  • Japanese journal of clinical oncology
  • 2012
VIEW 2 EXCERPTS
CITES BACKGROUND & METHODS

References

Publications referenced by this paper.
SHOWING 1-10 OF 31 REFERENCES

Author response: a different view of ‘‘standards’’ in the treatment of aggressive lymphomas

M Pfreundschuh, M. Loeffler
  • Blood
  • 2004
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Treatment of non-Hodgkin's lymphoma.

  • The New England journal of medicine
  • 1993
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL